RARRES2 and metabolic dysfunction-associated steatotic liver disease: Chemerin’s metabolic effects also extend to hepatic lipid accumulation, where elevated chemerin levels are linked to non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) [31].